PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
13.37%
Cash & equivalents growing 13.37% while GNPX's declined -6.00%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
13.37%
Below half of GNPX's -6.00%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.78%
Below half of GNPX's -4.60%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.38%
Below half GNPX's 5.88%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
Below half of GNPX's 1.70%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Below half of GNPX's -4.52%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-8.08%
Less than half of GNPX's 9.09%. David Dodd sees a more disciplined AP approach or lower volume.
2.29%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
8.08%
Higher Deferred Revenue (Current) Growth compared to GNPX's zero value, indicating better performance.
-2.29%
Less than half of GNPX's 146.64%. David Dodd sees fewer expansions in other current obligations.
-6.99%
Less than half of GNPX's 70.66%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.38%
Higher Total Non-Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-9.31%
Less than half of GNPX's 70.66%. David Dodd sees far fewer liability expansions relative to competitor.
10.53%
Above 1.5x GNPX's 0.44%. Michael Burry suspects heavy new equity expansion or dilution.
-2.12%
Below half GNPX's -6.14%. Michael Burry suspects major net losses or high dividends vs. competitor.
-7.96%
Less than half of GNPX's -7042253621.13%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
13.80%
Below half GNPX's -5.43%. Michael Burry sees potential underperformance in building shareholder capital.
12.46%
Below half GNPX's -4.52%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-16.56%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
-13.63%
Less than half of GNPX's 6.00%. David Dodd sees better deleveraging or stronger cash buildup than competitor.